Deep learning identified minimal mutations for cross-reactive anti-PD-L1 antibodies
A deep-learning model trained on deep-mutational-scanning sequence–binding data selected minimal mutation combinations for a human anti-PD-L1 antibody with mouse cross-reactivity. Variants with four to five substitutions showed in-vitro and cellular binding comparable to conventionally recombined variants with 13–15 substitutions; the paper also reports blockade assays and therapeutic activity in a mouse tumor model. These are preclinical antibody-engineering results, not evidence of human efficacy. The preprint reports patent applications related to the subject matter.
Technology: Deep-learning model trained on deep-mutational-scanning sequence–binding data
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The preprint reports in-vitro and cellular binding properties of selected variants, PD-1/PD-L1 competition/blockade assays, epitope mapping and mouse tumor-model assessment. The 4–5 substitution variants are compared with highly mutated variants requiring 13–15 substitutions.
- Still unknown: Mouse-model activity is preclinical and does not establish human therapeutic efficacy. The preprint reports patent applications relevant to the work; no freedom-to-operate or patent-priority conclusion is made.
- AI role: A deep-learning model trained on DMS-derived sequence-binding data selected minimal mutation combinations for experimental antibody characterization.
Evidence sources: https://www.biorxiv.org/content/10.64898/2026.07.15.738714v1.full · https://www.biorxiv.org/content/10.64898/2026.07.15.738714v1 · https://api.biorxiv.org/details/biorxiv/10.64898/2026.07.15.738714
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv v1 indexed full-text/abstract, author-affiliation metadata and official API metadata; direct page open returned 403..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.